Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nogapendekin Alfa Inbakicept and iNKT Cells in Severe Community-Acquired Pneumonia
NCT07492875Phase 3Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Allogeneic CAR-T, Cytokines & Interferons, Lymphokine-Activated Killer Cells
01
Overview
A Phase 3 trial of nogapendekin alfa inbakicept, agenT-797 in community acquired pneumonia (CAP), acute respiratory distress syndrome (ARDS), sepsis, sponsored by ImmunityBio, Inc.. Planned start Apr 2026; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptagenT-797
03
Conditions
community acquired pneumonia (CAP)acute respiratory distress syndrome (ARDS)sepsis
Beyond the preview
Go deeper on NCT07492875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492875.